BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36942380)

  • 21. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
    Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
    J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
    Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
    Billett AL; Carls A; Gelber RD; Sallan SE
    Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
    August KJ; Miller WP; Dalton A; Shinnick S
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
    Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
    Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
    Ebeid EN; Kamel MM; Ali BA
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity and toxicity of intramuscular 1000 iu/m
    Sidhu J; Masurekar AN; Gogoi MP; Fong C; Ioannou T; Lodhi T; Parker C; Liu J; Kirkwood AA; Moorman AV; Das K; Goulden NJ; Vora A; Saha V; Krishnan S
    Br J Haematol; 2022 Jul; 198(1):142-150. PubMed ID: 35348200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
    Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
    Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
    Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
    Sikorska-Fic B; Makowska K; Rokicka-Milewska R
    Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.